Laura E. Niklason - Sep 14, 2023 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role: President, CEO and Director, Director
Signature: /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Stock symbol: HUMA
Transactions as of: Sep 14, 2023
Transactions value $: -$5,560,000
Form type: 4
Date filed: 9/15/2023, 04:06 PM
Previous filing: Aug 21, 2023
Next filing: Oct 10, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HUMA	Common Stock	Sale	-$5.56M	-2M	-24.42%	$2.78	6.19M	Sep 14, 2023	By Ayabudge LLC	F1
holding	HUMA	Common Stock						1.27M	Sep 14, 2023	Direct
holding	HUMA	Common Stock						510K	Sep 14, 2023	By spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

Content

The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.